%0 Journal Article
%T Antithrombotic properties of Tafamidis: An additional protective effect for transthyretin amyloid cardiomyopathy patients.
%A Ministrini S
%A Niederberger R
%A Akhmedov A
%A Beer G
%A Puspitasari YM
%A Franzini M
%A Vergaro G
%A Cannie DE
%A Elliott P
%A Kahr PC
%A Hock C
%A Kobza R
%A Toggweiler S
%A Lüscher TF
%A Camici GG
%A Stämpfli SF
%J Vascul Pharmacol
%V 156
%N 0
%D 2024 Sep 17
%M 39029855
%F 5.738
%R 10.1016/j.vph.2024.107411
%X <B>BACKGROUND: </B>Tafamidis is a molecular chaperone that stabilizes the transthyretin (TTR) homo-tetramer, preventing its dissociation and consequent deposition as amyloid fibrils in organ tissues. Tafamidis reduces mortality and the incidence of hospitalization for cardiovascular causes in patients with TTR amyloid (ATTR) cardiomyopathy. As ATTR cardiomyopathy is associated with a high risk of thromboembolic complications, we hypothesized that tafamidis may have a direct ancillary anti-thrombotic effect.<BR><B>METHODS: </B>Primary human aortic endothelial cells (HAECs) were treated with tafamidis at clinically relevant concentrations and with plasma of patients, before and after the initiation of treatment with tafamidis. The expression of TF was induced by incubation with Tumor Necrosis Factor α (TNFα). Intracellular expression of tissue factor (TF) was measured by western blot. TF activity was measured by a colorimetric assay. Gene expressions of TF were measured by quantitative polymerase chain reaction.<BR><B>RESULTS: </B>Treatment with tafamidis dose-dependently reduced the expression and activity of TNFα-induced TF. This effect was confirmed in cells treated with patients' plasma. Signal Transducer and Activator of Transcription 3 (STAT3) phosphorylation was significantly inhibited by tafamidis. Incubation of HAECs with tafamidis and the STAT3 activator colivelin partially rescued the expression of TF.<BR><B>CONCLUSIONS: </B>Treatment with tafamidis lowers the thrombotic potential in human primary endothelial cells by reducing TF expression and activity. This previously unknown off-target effect may provide a novel mechanistic explanation for the lower number of thromboembolic complications in ATTR cardiomyopathy patients treated with tafamidis.